Search

Displaying results 3551 - 3560 of 10000 in total
  1. Drug

    Asparaginase Escherichia coli

    go.drugbank.com/drugs/DB00023
    ApprovedInvestigational

    Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia … Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997].

    Synonyms: Asparaginase (E. coli), E. coli AsparaginaseProducts: LEUNASE FOR INJECTION 10,000 iu/vial, LEUNASE ENJEKTABL 10.000 IU FLAKON, 1 ADET
  2. Drug

    Nelutroctiv

    go.drugbank.com/drugs/DB21554
    Investigational

    Nelutroctiv has a monoisotopic molecular weight of 543.13 Da. … Nelutroctiv is under investigation in clinical trial NCT05662215 (A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants).

  3. Drug

    Amber

    go.drugbank.com/drugs/DB14326
    Investigational

    Amber is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Telratolimod

    go.drugbank.com/drugs/DB19590
    Investigational

    Telratolimod has a monoisotopic molecular weight of 593.47 Da. … Telratolimod is under investigation in clinical trial NCT06680479 (Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

  5. Drug

    Rezivertinib

    go.drugbank.com/drugs/DB21471
    Investigational

    Rezivertinib has a monoisotopic molecular weight of 486.24 Da. … Rezivertinib is under investigation in clinical trial NCT06955325 (Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations).

  6. Drug

    Tuxobertinib

    go.drugbank.com/drugs/DB21508
    Investigational

    Tuxobertinib has a monoisotopic molecular weight of 560.19 Da. … Tuxobertinib is under investigation in clinical trial NCT04209465 (A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.).

  7. Drug

    Poloxamer 407

    go.drugbank.com/drugs/DB11252
    Investigational

    Poloxamer 407 is used as an emulsifying agent and solubilizing agent in cosmetic and personal products such as contact lens cleaning solutions. … It consists of a central hydrophobic block of polypropylene glycol that is flanked on each side by polyethylene glycol blocks, both hydrophilic in nature.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Tabelecleucel

    go.drugbank.com/drugs/DB17072
    ApprovedInvestigational

    Tabelecleucel is an innovative therapy that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells (CTLs). … [A253292,A253297,L43557] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended tabelecleucel be granted marketing authorization for the treatment of adult and

  9. Drug

    Tifuvirtide

    go.drugbank.com/drugs/DB05413
    Investigational

    It has received fast-track designation from the FDA and is in Phase I/II clinical testing.

    Categories: Gene Products, env, env Gene Products, Human Immunodeficiency Virus
  10. Drug

    Aclidinium

    go.drugbank.com/drugs/DB08897
    Approved

    FDA approved on July 24, 2012. … Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD).